Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Biotest AG banner

Biotest AG
SWB:BIO

Watchlist Manager
Biotest AG Logo
Biotest AG
SWB:BIO
Watchlist
Price: 43 EUR Market Closed
Market Cap: €1.7B
Write Note Create Alert Ask AI

Wall St Price Targets

BIO Price Targets Summary
Biotest AG

There are no price targets for BIO.
BIO Lowest Forecast
Not Available
BIO Average Forecast
Not Available
BIO Highest Forecast
Not Available
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
Biotest AG Competitors:
Price Targets
EOLS
Evolus Inc
158% Upside
AMAL
Amalgamated Bank
3% Upside
AMSF
Amerisafe Inc
12% Upside
RLMD
Relmada Therapeutics Inc
158% Upside
EOLS
Evolus Inc
158% Upside
AMAL
Amalgamated Bank
3% Upside
AMSF
Amerisafe Inc
12% Upside
RLMD
Relmada Therapeutics Inc
158% Upside

Revenue
Forecast

7% / Year
Past Growth
-1% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat
7% / Year
Past Growth
-1% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat

Over the last 8 years, the compound annual growth rate for Revenue has been 7%. The projected CAGR for the next 1 year is -1%.

What are analyst estimates?

Gross Profit
Forecast

4% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
4% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for Biotest AG

Operating Income
Forecast

12% / Year
Past Growth
25% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat
12% / Year
Past Growth
25% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat

Over the last 8 years, the compound annual growth rate for Operating Income has been 12%. The projected CAGR for the next 1 year is 25%.

What are analyst estimates?

Pre-Tax Income
Forecast

9% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
9% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 8 years, the compound annual growth rate for Pre-Tax Income has been 9%.

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

What are analyst estimates?

Continue BIO Research

Summary
BIO intrinsic value, competitors valuation, and company profile.
DCF Valuation
BIO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BIO stock valuation using valuation multiples.
Wall St Estimates
BIO price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BIO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Biotest AG listings:
LSE • EUR
0N6Z
 XETRA • EUR
BIO
 F • EUR
BIO
 XETRA • EUR
BIO3
 OTC • USD
BIESF
 LSE • EUR
0N70
 XBER • EUR
BIO
 XHAM • EUR
BIO
 XETRA • EUR
BIO0
 XETRA • EUR
BIO2
 XETRA • EUR
BIO1
 F • EUR
BIO3
 OTC • USD
BTTAY
 XMUN • EUR
BIO
 SWB • EUR
BIO3
 DUS • EUR
BIO
 XHAM • EUR
BIO3
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is BIO's stock price target?
Not Available

BIO does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for Biotest AG?
Projected CAGR
-1%

Over the last 8 years, the compound annual growth rate for Revenue has been 7%. The projected CAGR for the next 1 year is -1%.

What is the Operating Income forecast for Biotest AG?
Projected CAGR
25%

Over the last 8 years, the compound annual growth rate for Operating Income has been 12%. The projected CAGR for the next 1 year is 25%.

Back to Top
ALPHA SPREAD
Follow us
Join 349,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett